Nelson Teng, M.D.
Professor, Stanford University

Nelson Teng, M.D. has extensive scientific and medical insight with respect to cancer, women’s health, surgery and monoclonal antibodies. He also has a vast network of relationships with leading scientists and physicians throughout the world and has been the founder and director of multiple biotechnology companies. Since 1986, Nelson has been chief of gynecologic oncology at Stanford University’s School of Medicine. Nelson is a named inventor on fifteen patents and is an author of more than 100 publications.

Over the past 20 years, the scientific research at Nelson’s laboratory at Stanford University has focused on cancer biology and gynecologic diseases. His laboratory has created numerous monoclonal antibodies of clinical interest, including the first human therapeutic monoclonal antibody to be taken into clinical trials. Nelson has also been a principal investigator for more than 30 cancer clinical trials.

Among his many professional honors, Nelson has been honorary senior registrar at Hammersmith Hospital (London), Royal Postgraduate College and research scientist at the Massachusetts Institute of Technology. He is a fellow of the American College of Surgeons and the American College of Obstetricians and Gynecologists, former president of the Western Association of Gynecologic Oncologists and former chairman of the uterine and cervical cancer committee and member of both the ovarian cancer committee and the cervical cancer screening committee of the National Comprehensive Cancer Network.

Nelson has also served on various committees within the Gynecologic Oncology Group, a national clinical trial consortium sponsored by the National Cancer Institute. Nelson is board certified in gynecology, gynecologic oncology and obstetrics. In addition to his many academic and clinical accomplishments, Nelson has also been an active entrepreneur over the past twenty years.

He was a founder of several companies with Barr, including women’s health care company Adeza Biomedical (ADZA), biotech company Univax Biologics (IPO, then acquired by NABI) and women’s health care company Vesta (acquired by Pfizer). He has also served as vice president of research at Adeza Biomedical. Nelson also has extensive experience in Asia and, with respect to biotechnology matters, has been an advisor to Asian governments and Asian-based venture capital funds such as Vertex and Mingly Capital.

Nelson received a PhD in biophysics from the University of California, Berkeley, an MD from the University of Miami and is a graduate of the postgraduate program at the Stanford University Graduate Business School.